PhoreMost Ltd. and ThinkCyte K.K have announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).
The partnership leverages both companies’ technologies in high-throughput drug discovery. These are PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterization and sorting platform, Ghost Cytometry. The aim is to develop differentiated therapies for a range of diseases with unmet clinical need.
Driven by advances in cell-based phenotypic screening tools and novel target discovery technologies, the power of phenotypic drug discovery (PDD) lies in its ability to find completely new drug targets and disease mechanisms. This provides not only new drug candidates, but alo a better understanding of disease.
PhoreMost’s SITESEEKER platform, based on the company’s ‘Protein Interference’ (PROTEINi) technology, probes the entire proteome to systematically unmask new and unanticipated druggable sites, directly linking them to useful therapeutic functions.
ThinkCyte has pioneered Ghost Cytometry, an approach that enables detection of novel, disease-related phenotypes. By combining SITESEEKER to identify novel druggable targets with Ghost Cytometry to identify subtle phenotypic changes in living cells, the partnership aims to develop a unique approach to high-content phenotypic screening.
PhoreMost and ThinkCyte collaboration will uncover novel targets
“PhoreMost has embraced the revolution in computational methods to transform the way we approach modern drug discovery,” said Benedict Cross, CTO of PhoreMost.
“By combining ThinkCyte’s AI-based platform to detect novel, disease-related phenotypes with our SITESEEKER phenotypic screening platform, we hope to more efficiently uncover a broad range of novel targets and translate them into high-quality first-in-class therapeutic assets.”
“We are very excited about the research partnership with PhoreMost, a leader in applying innovative approaches and technologies to open up new druggable spaces,” said Waichiro Katsuda, CEO at ThinkCyte.
“We have been privileged to work with drug discovery industry partners who share our vision of using AI to rethink traditional approaches in R&D and look forward to working together with PhoreMost to advance our technologies towards the shared goal of making meaningful impact for people suffering from serious diseases.”
Partnering 2030: The Biotech Perspective 2023
